Today, Ngam Advisors L.P. decides to keep it stake in Core Laboratories NV (CLB) to the level of $11,605,000

Today, Ngam Advisors L.P. decides to keep it stake in Core Laboratories NV (CLB) to the level of $11,605,000
Ngam Advisors L.P. decreased its position in Core Laboratories NV (NYSE:CLB) by 0.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 103,312 shares of the company’s stock after selling 565 shares during the period. Ngam Advisors L.P. owned about 0.23% of Core Laboratories NV worth $11,605,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. NEXT Financial Group Inc increased its position in shares of Core Laboratories NV by 784.3% in the third quarter. NEXT Financial Group Inc now owns 902 shares of the company’s stock worth $101,000 after buying an additional 800 shares during the period. Balentine LLC boosted its stake in shares of Core Laboratories NV by 44.3% in the second quarter. Balentine LLC now owns 893 shares of the company’s stock worth $111,000 after buying an additional 274 shares in the last quarter. MU Investments Co. Ltd. purchased a new stake in shares of Core Laboratories NV during the second quarter worth about $115,000. Advisory Services Network LLC boosted its stake in shares of Core Laboratories NV by 33.2% in the third quarter. Advisory Services Network LLC now owns 1,062 shares of the company’s stock worth $119,000 after buying an additional 265 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Core Laboratories NV by 10.0% in the third quarter. Daiwa Securities Group Inc. now owns 1,100 shares of the company’s stock worth $124,000 after buying an additional 100 shares in the last quarter.

Shares of Core Laboratories NV (NYSE:CLB) opened at 109.13 on Friday. Core Laboratories NV has a 1-year low of $84.50 and a 1-year high of $135.49. The stock has a market cap of $4.81 billion, a price-to-earnings ratio of 73.94 and a beta of 1.40. The stock’s 50 day moving average price is $106.09 and its 200-day moving average price is $114.64.

Core Laboratories NV (NYSE:CLB) last posted its quarterly earnings data on Wednesday, October 19th. The company reported $0.38 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.38. Core Laboratories NV had a return on equity of 108.46% and a net margin of 10.17%. The firm had revenue of $143.50 million for the quarter, compared to analysts’ expectations of $155.72 million. During the same period in the previous year, the firm earned $0.83 EPS. The business’s quarterly revenue was down 27.3% on a year-over-year basis. On average, equities research analysts forecast that Core Laboratories NV will post $1.52 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, November 22nd. Stockholders of record on Friday, October 21st were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Wednesday, October 19th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.02%. Core Laboratories NV’s payout ratio is currently 149.66%.

CLB has been the topic of a number of research reports. Zacks Investment Research upgraded Core Laboratories NV from a “sell” rating to a “hold” rating in a research note on Thursday, October 6th. Citigroup Inc. lowered their price objective on Core Laboratories NV from $118.00 to $116.00 and set a “neutral” rating on the stock in a research note on Monday, September 12th. Credit Suisse Group AG initiated coverage on Core Laboratories NV in a research note on Thursday, September 1st. They issued a “neutral” rating and a $115.00 price objective on the stock. Cowen and Company restated a “market perform” rating and issued a $105.00 price objective on shares of Core Laboratories NV in a research note on Saturday, October 22nd. Finally, Loop Capital initiated coverage on Core Laboratories NV in a research note on Friday, September 30th. They issued a “hold” rating and a $120.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $121.50.

Core Laboratories NV Company Profile

Related posts

Leave a Comment